Vera Therapeutics, Inc. Class A

XNASHealth care

Last traded price · USD

$31.95

−0.06%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:27 IST · A quote does not mean the product is available to trade on your account.

Day's open: $31.55
Previous close: $31.97
Volume: 144,870
Day's high: $32.15
Day's low: $31.30

In brief

Vera Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $2.30B.
Its shares closed at $31.97 on 4 Nov 2026, up 31.3% over the past year.
From India you can buy VERA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Vera Therapeutics, Inc. (VERA) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole VERA share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade VERA options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

7.2 days to cover short interest
13.6M shares were sold short at the 15 Oct 2026 settlement, 18.9% of the 72.1M shares outstanding; covering them would take 7.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Ahead of SPY, in line with its sector fund XLV over 1 year
1 month: +8.7% (SPY −1.6%, XLV +13.5%). 3 months: +5.3% (SPY −0.4%, XLV +15.5%). 1 year: +31.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: VERA, SPY and XLV · as of 4 Nov 2026
Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $31.97 was 0.4% above its 50-day average ($31.83) and 13.0% below its 200-day average ($36.73). It has closed below the 200-day for 78 sessions, since 17 Jul 2026. The 50-day average crossed below the 200-day on 15 Jun 2026, 99 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
27% of the way up its 52-week range
Closed at $31.97 on 4 Nov 2026: 43.0% below the 52-week high of $56.05 (24 Dec 2025) and 38.7% above the low of $23.05 (6 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+8.7%

6 months−12.6%

1 year+31.3%

5 years+79.6%

Newswire

About

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Website

Notable moves

June 2, 2025
+67.49%
January 25, 2024
+48.71%
January 4, 2023
−64.70%

Vera Therapeutics, Inc. Class A

XNASHealth care

Last traded price · USD

$31.95

−0.06%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:27 IST · A quote does not mean the product is available to trade on your account.

Day's open: $31.55
Previous close: $31.97
Volume: 144,870
Day's high: $32.15
Day's low: $31.30

In brief

Vera Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $2.30B.
Its shares closed at $31.97 on 4 Nov 2026, up 31.3% over the past year.
From India you can buy VERA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Vera Therapeutics, Inc. (VERA) shares from India?

Do I need the price of a whole VERA share to invest?

How much can I invest in US stocks in a year?

Can I trade VERA options or futures?

Insights

Quotes run fifteen minutes behind.

7.2 days to cover short interest
13.6M shares were sold short at the 15 Oct 2026 settlement, 18.9% of the 72.1M shares outstanding; covering them would take 7.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Ahead of SPY, in line with its sector fund XLV over 1 year
1 month: +8.7% (SPY −1.6%, XLV +13.5%). 3 months: +5.3% (SPY −0.4%, XLV +15.5%). 1 year: +31.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: VERA, SPY and XLV · as of 4 Nov 2026
Above its 50-day average, below its 200-day
The 4 Nov 2026 close of $31.97 was 0.4% above its 50-day average ($31.83) and 13.0% below its 200-day average ($36.73). It has closed below the 200-day for 78 sessions, since 17 Jul 2026. The 50-day average crossed below the 200-day on 15 Jun 2026, 99 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
27% of the way up its 52-week range
Closed at $31.97 on 4 Nov 2026: 43.0% below the 52-week high of $56.05 (24 Dec 2025) and 38.7% above the low of $23.05 (6 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+8.7%

6 months−12.6%

1 year+31.3%

5 years+79.6%

Newswire

About

Website

Notable moves

June 2, 2025
+67.49%
January 25, 2024
+48.71%
January 4, 2023
−64.70%

Vera Therapeutics, Inc. Class A

Vera Therapeutics, Inc. in brief

7.2 days to cover short interest

Ahead of SPY, in line with its sector fund XLV over 1 year

Above its 50-day average, below its 200-day

27% of the way up its 52-week range

Vera Therapeutics, Inc. Class A

Vera Therapeutics, Inc. in brief

7.2 days to cover short interest

Ahead of SPY, in line with its sector fund XLV over 1 year

Above its 50-day average, below its 200-day

27% of the way up its 52-week range